CN101494980A - HMG-CoA还原酶抑制剂的多晶型形式及其应用 - Google Patents

HMG-CoA还原酶抑制剂的多晶型形式及其应用 Download PDF

Info

Publication number
CN101494980A
CN101494980A CNA2007800268329A CN200780026832A CN101494980A CN 101494980 A CN101494980 A CN 101494980A CN A2007800268329 A CNA2007800268329 A CN A2007800268329A CN 200780026832 A CN200780026832 A CN 200780026832A CN 101494980 A CN101494980 A CN 101494980A
Authority
CN
China
Prior art keywords
polymorphic
isopropyl
fluorophenyl
dihydroxy
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800268329A
Other languages
English (en)
Chinese (zh)
Inventor
G·C·亚瓦
M·巴吉尔
V·P·潘德亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38957150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101494980(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN101494980A publication Critical patent/CN101494980A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2007800268329A 2006-07-14 2007-07-13 HMG-CoA还原酶抑制剂的多晶型形式及其应用 Pending CN101494980A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1629/DEL/2006 2006-07-14
IN1629DE2006 2006-07-14

Publications (1)

Publication Number Publication Date
CN101494980A true CN101494980A (zh) 2009-07-29

Family

ID=38957150

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800268329A Pending CN101494980A (zh) 2006-07-14 2007-07-13 HMG-CoA还原酶抑制剂的多晶型形式及其应用

Country Status (12)

Country Link
US (1) US20080153896A1 (https=)
EP (1) EP2049102A4 (https=)
JP (1) JP2009543773A (https=)
CN (1) CN101494980A (https=)
AR (1) AR063469A1 (https=)
AU (1) AU2007274724B2 (https=)
BR (1) BRPI0714361A2 (https=)
CL (1) CL2007002044A1 (https=)
MX (1) MX2009000439A (https=)
RU (1) RU2009105089A (https=)
TW (1) TW200811101A (https=)
WO (1) WO2008010087A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438595A (zh) * 2015-03-31 2017-12-05 大元制药株式会社 晶型及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
KR102218320B1 (ko) * 2019-07-12 2021-02-23 대원제약주식회사 (3r,5r)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법, 및 이에 사용되는 중간체의 제조방법

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) * 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3868460A (en) * 1967-02-06 1975-02-25 Boehringer Sohn Ingelheim Therapeutic compositions and method
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3934032A (en) * 1969-02-21 1976-01-20 Imperial Chemical Industries Limited Alkanolamine derivatives for treating hypertension
FI52570C (fi) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3663570A (en) * 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
AT296986B (de) * 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
BE755071A (fr) * 1969-09-17 1971-02-22 Warner Lambert Pharmaceutical Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
US3879554A (en) * 1970-03-20 1975-04-22 Farmaceutici Italia Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders
US4032648A (en) * 1970-04-06 1977-06-28 Science Union Et Cie Method and compositions containing thiochroman compounds for treating cardiac rhythm disorders
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US3932645A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
BE795735A (fr) * 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
DE2322232A1 (de) * 1973-05-03 1974-11-14 Thomae Gmbh Dr K Neue acylaminosaeureamide
US4011258A (en) * 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
AT334385B (de) * 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1501632A (en) * 1974-06-28 1978-02-22 Cm Ind Aromatic ketones having cardiovascular activity
DE2635209C2 (de) * 1975-08-15 1983-01-27 Sandoz-Patent-GmbH, 7850 Lörrach 4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
HU172137B (hu) * 1976-03-02 1978-06-28 Gyogyszerkutato Intezet Sposob poluchenija zamehhjonnykh proizvodnykh fenoksi-propanolamina
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
AU543804B2 (en) * 1980-10-31 1985-05-02 Takeda Chemical Industries Ltd. Amides having bicyclic substituents on nitrogen
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
JPS57171968A (en) * 1981-04-17 1982-10-22 Kyowa Hakko Kogyo Co Ltd 1,4-dihydropyridine derivative
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPS60222472A (ja) * 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
US4672068A (en) * 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1988007525A1 (fr) * 1987-03-27 1988-10-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Enantiomeres de 1,4-dihydropyridine
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
GB8907256D0 (en) * 1989-03-31 1989-05-17 Rech Et D Applic Scient Scras New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
JP3286745B2 (ja) * 1993-09-10 2002-05-27 日清食品株式会社 シクロヘキサンジウレア誘導体及びその製法
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
KR0136986B1 (ko) * 1993-12-31 1998-04-25 김준웅 신규 징코라이드 유도체와 이의 제조방법
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US6168986B1 (en) * 1998-01-23 2001-01-02 Micron Technology, Inc. Method of making a sacrificial self-aligned interconnect structure
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1212089B1 (en) * 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistic combination of roflumilast and salmeterol
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
CA2456732C (en) * 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
US7361772B2 (en) * 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7169094B2 (en) * 2002-10-09 2007-01-30 Corepole, Inc. Circular fitness apparatus
US20040102511A1 (en) * 2002-11-21 2004-05-27 Jitendra Sattigeri Substituted pyrrole derivatives
US7762935B2 (en) * 2003-02-20 2010-07-27 Doble William C Exercise apparatus resistance unit
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
US6884226B2 (en) * 2003-07-02 2005-04-26 Fred Pereira Crib patting device
BRPI0614341A2 (pt) * 2005-08-15 2011-03-29 Wyeth Corp composto; método para o tratamento de um distúrbio do sistema nervoso central relacionado com o receptor de 5-ht6 ou afetado por ele em um paciente que deste necessite; composição farmacêutica; e processo

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438595A (zh) * 2015-03-31 2017-12-05 大元制药株式会社 晶型及其制备方法
CN107438595B (zh) * 2015-03-31 2021-05-18 大元制药株式会社 晶型及其制备方法

Also Published As

Publication number Publication date
US20080153896A1 (en) 2008-06-26
WO2008010087A3 (en) 2009-04-23
TW200811101A (en) 2008-03-01
EP2049102A4 (en) 2010-12-22
JP2009543773A (ja) 2009-12-10
MX2009000439A (es) 2009-02-04
CL2007002044A1 (es) 2008-06-13
AR063469A1 (es) 2009-01-28
BRPI0714361A2 (pt) 2013-03-26
AU2007274724A1 (en) 2008-01-24
WO2008010087A2 (en) 2008-01-24
EP2049102A2 (en) 2009-04-22
AU2007274724B2 (en) 2012-07-26
RU2009105089A (ru) 2010-08-27

Similar Documents

Publication Publication Date Title
CZ20014126A3 (cs) Indolové deriváty jako inhibitory p38 kinasy
JP2009235083A (ja) アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
HUE026408T2 (en) Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
KR20130038258A (ko) 삭사글립틴 중간체, 삭사글립틴 다형 및 이들의 제조 방법
CN101494980A (zh) HMG-CoA还原酶抑制剂的多晶型形式及其应用
US20060122403A1 (en) Atorvastatin calcium form vi or hydrates thereof
US20080167477A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
WO2018209972A1 (zh) 抗焦虑氘代化合物及其医药用途
CN114026085A (zh) (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
JP2007507497A (ja) フルバスタチンナトリウムの多形の調製方法
US20100260851A1 (en) Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090018182A1 (en) Crystalline forms of atorvastatin
AU2016200492B2 (en) Novel crystal form
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN116768909B (zh) Vanin酶抑制剂的盐型、晶型及其制备方法和应用
US8383627B2 (en) Crystalline polymorph of doxazosin mesylate (form IV) and process for preparation thereof
CN106608824B (zh) 芳酸酯类化合物及其制备方法和用途
US20110263670A1 (en) Novel polymorphs of sunitinib and processes for their preparation
US12227506B2 (en) Crystalline polymorphs of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
EP2389360A2 (en) A process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
US20100204296A1 (en) Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2023284872A1 (zh) 一种dpp4抑制活性化合物的多晶型及其制备方法
CN110028439A (zh) 邻苯二甲酰亚胺类衍生物及其制备方法和用途
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JPH089593B2 (ja) 環状エノ−ル誘導体およびその製造法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090729